By Deena Beasley June 25 (Reuters) – Launch prices for prescription medicines approved by U.S. regulators in 2025 fell from the previous year, but remained high at a median of $216,000 due to
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
BRIEF-Jin Air Co Transport Ministry Approves Merger With Air Busan
Jin Air Co Ltd: * TRANSPORT MINISTRY APPROVES MERGER WITH AIR BUSAN Source text: Further…
SMIC says AI chip supply chain will remain tight through 2027
By Che Pan and Eduardo Baptista BEIJING, Nov 13 (Reuters) - China's biggest contract chipmaker,…
Striped socks keep FamilyMart a step ahead in Japan's convenience store wars
By Mariko Katsumura and Yusuke Ogawa TOKYO, Nov 13 (Reuters) - For some people, the…
